Rewarding effects elicited by cocaine microinjections into the ventral tegmental area of C57BL/6 mice: involvement of dopamine D1 and serotonin1B receptors.

Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7608025 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0033-3158 (Print) Linking ISSN: 00333158 NLM ISO Abbreviation: Psychopharmacology (Berl) Subsets: MEDLINE

Original Publication: Berlin, New York, Springer-Verlag.

Reward*; Anesthetics, Local/*pharmacology ; Cocaine/*pharmacology ; Receptor, Serotonin, 5-HT1B/*physiology ; Receptors, Dopamine D1/*physiology ; Ventral Tegmental Area/*drug effects; Analysis of Variance ; Animals ; Behavior, Animal/drug effects ; Benzazepines/pharmacology ; Dopamine Antagonists/pharmacology ; Dose-Response Relationship, Drug ; Drug Interactions ; Male ; Mice ; Mice, Inbred C57BL ; Microinjections/methods ; Oxadiazoles/pharmacology ; Piperazines/pharmacology ; Reaction Time/drug effects ; Self Administration ; Serotonin Antagonists/pharmacology ; Spatial Behavior/drug effects ; Ventral Tegmental Area/physiology

Rationale: The role of ventral tegmental area (VTA) in mediating the rewarding effects of cocaine has not been extensively studied.
Objectives: We used the intracranial self-administration (ICSA) procedure to assess the involvement of the VTA in the rewarding effects of cocaine, and the effect of dopamine (DA) D(1)- and serotonin (5-HT)(1B)-receptor antagonists on ICSA of cocaine.
Methods: Adult male C57BL/6 mice were stereotaxically implanted, unilaterally, with a guide cannula either 1.5 or 2.3 mm above the VTA. After 1 week, mice were trained to discriminate between the two arms of a Y-maze over seven daily sessions, one arm being reinforced by intracranial cocaine microinjections. Starting from session 8, the D(1) and 5-HT(1B)-receptor antagonists were injected IP pre-test each day over five consecutive sessions.
Results: Mice injected into the VTA rapidly exhibited a preference for the cocaine-reinforced arm, whatever the dose of cocaine available (30 pmol or 150 pmol per injection), reaching optimum ICSA performance within 5 days. In contrast, mice injected 0.8 mm above the VTA did not discriminate between the arms of the maze and performed at random, except for one subject. Once the ICSA response was acquired, systemic pre-injections of either the D(1) (SCH23390; 25 microg/kg IP) or 5-HT(1B) (GR127935; 0.5 mg/kg IP) antagonist disrupted this behavior. Replacement of each antagonist by vehicle led to the reinstatement of intra-VTA cocaine self-administration.
Conclusions: The results of the present study suggest that VTA neurons play a critical role in mediating the rewarding effects of acute cocaine and that both D(1) and 5-HT(1B) receptors modulate these effects.

Brain Res. 1994 Jun 6;647(2):307-22. (PMID: 7522922)
Behav Brain Res. 1993 Jun 30;55(2):159-66. (PMID: 8395179)
Pharmacol Biochem Behav. 1997 Jul;57(3):407-12. (PMID: 9218264)
Eur J Neurosci. 1998 Apr;10 (4):1394-402. (PMID: 9749793)
Brain Res. 1987 Jul 28;416(2):283-8. (PMID: 3620961)
J Pharmacol Exp Ther. 1995 Sep;274(3):1414-24. (PMID: 7562516)
Brain Res. 2000 Jun 2;866(1-2):44-54. (PMID: 10825479)
Brain Res. 1987 Jun 23;414(1):77-84. (PMID: 3620924)
Mol Pharmacol. 1997 May;51(5):755-63. (PMID: 9145913)
J Neurosci. 2002 Aug 15;22(16):7225-33. (PMID: 12177217)
Psychopharmacology (Berl). 2000 Feb;148(3):314-21. (PMID: 10755745)
Nature. 1998 May 14;393(6681):175-8. (PMID: 9603521)
Neuropsychopharmacology. 2003 Jan;28(1):73-6. (PMID: 12496942)
Nat Neurosci. 1998 Jun;1(2):132-7. (PMID: 10195128)
Science. 1987 Sep 4;237(4819):1219-23. (PMID: 2820058)
Behav Pharmacol. 2001 Apr;12(2):109-16. (PMID: 11396515)
Neuropsychopharmacology. 2001 Mar;24(3):300-18. (PMID: 11166520)
Pharmacol Biochem Behav. 1985 Dec;23(6):1029-36. (PMID: 3936058)
Science. 1983 Aug 19;221(4612):773-5. (PMID: 6879176)
Pharmacol Biochem Behav. 1998 Sep;61(1):87-92. (PMID: 9715810)
Neurosci Lett. 1993 Nov 26;163(1):50-2. (PMID: 8295732)
J Neurosci. 2003 Oct 15;23(28):9305-11. (PMID: 14561857)
Neuropharmacology. 1994 Mar-Apr;33(3-4):367-86. (PMID: 7984275)
Psychopharmacology (Berl). 1991;103(4):455-61. (PMID: 2062985)
Nature. 1996 Feb 15;379(6566):606-12. (PMID: 8628395)
Psychopharmacology (Berl). 1996 Dec;128(4):351-8. (PMID: 8986005)
Eur J Pharmacol. 2003 Jan 17;459(2-3):239-45. (PMID: 12524152)
J Neurosci. 1996 May 1;16(9):3112-22. (PMID: 8622141)
J Neurosci. 1994 Nov;14(11 Pt 1):6763-7. (PMID: 7965077)
J Pharmacol Exp Ther. 1993 Oct;267(1):496-505. (PMID: 8229780)
Pharmacol Biochem Behav. 1993 May;45(1):239-42. (PMID: 8516365)
Eur J Neurosci. 1998 Jul;10(7):2371-9. (PMID: 9749765)
Psychopharmacology (Berl). 1996 Nov;128(2):150-60. (PMID: 8956376)
Pharmacol Biochem Behav. 2000 Nov;67(3):559-66. (PMID: 11164086)
Pharmacol Biochem Behav. 1980 Jun;12(6):965-8. (PMID: 7403209)
Pharmacol Biochem Behav. 1997 Jul;57(3):601-7. (PMID: 9218282)
Psychopharmacology (Berl). 1998 May;137(1):1-6. (PMID: 9631950)
Pharmacol Biochem Behav. 2000 May;66(1):221-5. (PMID: 10837864)
Ann N Y Acad Sci. 1992 Jun 28;654:509-12. (PMID: 1385935)
Mol Psychiatry. 2002;7(1):21-6. (PMID: 11803442)
J Neurosci. 1998 Dec 1;18(23):10078-89. (PMID: 9822762)
Gen Pharmacol. 1997 Sep;29(3):293-303. (PMID: 9378233)
J Neurosci. 2001 Aug 1;21(15):5841-6. (PMID: 11466456)
Brain Res. 1990 Jan 29;508(1):20-9. (PMID: 2337788)
Pharmacol Biochem Behav. 1982 Nov;17(5):901-4. (PMID: 6817350)
Brain Res. 1997 Sep 5;767(2):363-9. (PMID: 9367270)
J Neurochem. 2001 Nov;79(4):914-22. (PMID: 11723184)
Pharmacol Biochem Behav. 1996 Jan;53(1):5-9. (PMID: 8848459)
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7699-704. (PMID: 9636213)
Psychopharmacology (Berl). 1999 Jan;141(3):242-50. (PMID: 10027505)
J Neurosci. 1992 May;12(5):2000-6. (PMID: 1578282)
Neuropharmacology. 1996;35(11):1521-9. (PMID: 9025099)
Psychopharmacology (Berl). 2002 Mar;160(3):307-17. (PMID: 11889500)
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5300-5. (PMID: 11320258)
J Neurosci. 2002 Dec 15;22(24):10856-63. (PMID: 12486179)

0 (Anesthetics, Local)
0 (Benzazepines)
0 (Dopamine Antagonists)
0 (Oxadiazoles)
0 (Piperazines)
0 (Receptor, Serotonin, 5-HT1B)
0 (Receptors, Dopamine D1)
0 (Serotonin Antagonists)
2LLH6CEB40 (GR 127935)
I5Y540LHVR (Cocaine)

Date Created: 20040317 Date Completed: 20041220 Latest Revision: 20181113

20221213

10.1007/s00213-003-1767-5

15024548